Piramal Pharma Ltd vs Sandu Pharmaceuticals Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 04, 2026

Key Highlights

The Latest Trading Price of Piramal Pharma Ltd is ₹ 161.9 as of 30 Apr 15:30 . The P/E Ratio of Piramal Pharma Ltd changed from 991.5 on March 2024 to 0 on March 2022 . This represents a CAGR of -100.00% over 4 yearsThe P/E Ratio of Sandu Pharmaceuticals Ltd changed from 33.3 on March 2023 to 0 on March 2022 . This represents a CAGR of -100.00% over 5 years The Market Cap of Piramal Pharma Ltd changed from ₹ 8165 crore on March 2023 to ₹ 0 crore on March 2022 . This represents a CAGR of -100.00% over 5 yearsThe Market Cap of Sandu Pharmaceuticals Ltd changed from ₹ 50.43 crore on March 2023 to ₹ 0 crore on March 2022 . This represents a CAGR of -100.00% over 5 years The revenue of Piramal Pharma Ltd for the Mar '26 is ₹ 2811 crore as compare to the Dec '25 revenue of ₹ 2193 crore. This represent the growth of 28.18% The revenue of Sandu Pharmaceuticals Ltd for the Mar '26 is ₹ 0 crore as compare to the Dec '25 revenue of ₹ 0 crore. This represent the decline of 0% The ebitda of Piramal Pharma Ltd for the Mar '26 is ₹ 344.37 crore as compare to the Dec '25 ebitda of ₹ 208.12 crore. This represent the growth of 65.47% The ebitda of Sandu Pharmaceuticals Ltd for the Mar '26 is ₹ 0 crore as compare to the Dec '25 ebitda of ₹ 0 crore. This represent the decline of 0% The net profit of Piramal Pharma Ltd changed from ₹ -88.64 crore to ₹ -8.83 crore over 8 quarters. This represents a CAGR of -68.44% The net profit of Sandu Pharmaceuticals Ltd changed from ₹ 0.17 crore to ₹ 0 crore over 8 quarters. This represents a CAGR of -100.00% The Dividend Payout of Piramal Pharma Ltd changed from 18.07 % on March 2022 to 2.68 % on March 2025 . This represents a CAGR of -37.94% over 4 yearsThe Dividend Payout of Sandu Pharmaceuticals Ltd changed from 36.33 % on March 2021 to 49.86 % on March 2025 . This represents a CAGR of 6.54% over 5 years .

About Piramal Pharma Ltd

Piramal Pharma Limited was incorporated on March 4, 2020 as a Public Limited Company and registered with the RoC. The Company offers a portfolio of differentiated products and services through end-to-end manufacturing capabilities across 17 global facilities and a global distribution network in over 100 countries.
It includes an integrated CDMO business, CHG business and ICH business, selling over-the-counter products in India.
In addition, it has a joint venture with Allergan, a leader in ophthalmology in the Indian formulations market. PPL is a leading pharmaceutical company with global operations, providing end-to-end pharma services to customers and a portfolio of differentiated pharma products across a domestic and global distribution network.
It operate under three business verticals - Piramal Pharma Solutions, an integrated contract development and manufacturing organization (CDMO) having a product suite in niche areas such as highly potent Active pharmaceutical ingredients (APIs), Finished dosage forms (FDFs), antibody drug conjugates, potent sterile injectable, hormonal oral solid dosage forms, biologics and vaccines; Piramal Critical Care, a complex hospital generics (CHG) business in the areas of inhalation anaesthesia, injectable anaesthesia and pain management, intrathecal therapy and other injectable; and India consumer healthcare (ICH) business, selling well-known OTC brands.

About Sandu Pharmaceuticals Ltd

Sandu Pharmaceuticals Ltd (SPL) was established in 1985.
The Company is mainly engaged in the business of manufacturing and trading of Ayurvedic medicines under the brand name SANDU. SPL came out with a public issue of 17.70 lac equity shares at par, aggregating Rs 1.77 cr, in Sep.'94, to part-finance its new project in Goa costing Rs 7.28 cr to manufacture ayurvedic medicines and formulations.
This plant employs the latest material handling systems and other modern machinery and has the most hygienic production facilities to attain the highest possible quality standards.
Ayurvedic products have a very good market in India and abroad due to their minimal side effects. The company commenced commercial production of Ayurvedic Medicines & Formulations, at the Goa plant in 1996-97.
Thereafter, it commenced production of manufacturing Unit II in Goa from May, 2002.

FAQs for the comparison of Piramal Pharma Ltd and Sandu Pharmaceuticals Ltd

Which company has a larger market capitalization, Piramal Pharma Ltd or Sandu Pharmaceuticals Ltd?

Market cap of Piramal Pharma Ltd is 21,520 Cr while Market cap of Sandu Pharmaceuticals Ltd is 42 Cr

What are the key factors driving the stock performance of Piramal Pharma Ltd and Sandu Pharmaceuticals Ltd?

The stock performance of Piramal Pharma Ltd and Sandu Pharmaceuticals Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Piramal Pharma Ltd and Sandu Pharmaceuticals Ltd?

As of May 4, 2026, the Piramal Pharma Ltd stock price is INR ₹161.9. On the other hand, Sandu Pharmaceuticals Ltd stock price is INR ₹44.0.

How do dividend payouts of Piramal Pharma Ltd and Sandu Pharmaceuticals Ltd compare?

To compare the dividend payouts of Piramal Pharma Ltd and Sandu Pharmaceuticals Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.